» Articles » PMID: 12640201

Identifying Recent HIV Infections Using the Avidity Index and an Automated Enzyme Immunoassay

Overview
Date 2003 Mar 18
PMID 12640201
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

We evaluated a procedure for identifying recent HIV infections, using sequential serum samples from 47 HIV-positive persons for whom the seroconversion date could be accurately estimated. Each serum sample was divided into two aliquots: one diluted with phosphate-buffered saline and the other diluted with 1 M guanidine. We assayed the aliquots with the automated AxSYM HIV1/2gO test (Abbott Diagnostics Division), without modifying the manufacturer's protocol. We then calculated the avidity index (AI): the ratio of the sample/cutoff value for the guanidine aliquot to that of the phosphate-buffered saline aliquot. We analyzed 216 serum samples: 34 samples were collected within 6 months of seroconversion (recent seroconversions), and 182 were collected after 6 months. The mean AIs, by time from seroconversion, were 0.68 +/- 0.16 (within 6 months) and 0.98 +/- 0.10 (after 6 months) (P < 0.0001). AI of <0.90 correctly identified 88.2% of recent infections but misclassified as recent infections 13.2% of serum samples collected afterward. The probability of an infection being classified as recent and having AI of > or = 0.90 would be 0.7% in a population with 5% recent infections. AI can identify with a certain degree of accuracy recent HIV infections, and being a quantitative index, it provides different levels of sensitivity and specificity, depending on the selected cutoff value. The standard assay procedure is not modified. This test is simple and inexpensive and could be used for surveillance, decision-making in treatment, and prevention.

Citing Articles

HIV testing: the cornerstone of HIV prevention efforts in the USA.

Heffelfinger J, Owen S, Hendry R, Lansky A Future Virol. 2023; 6(11).

PMID: 37965646 PMC: 10644277. DOI: 10.2217/fvl.11.114.


Development of a multiassay algorithm (MAA) to identify recent HIV infection in newly diagnosed individuals in Indonesia.

Wulan W, Yunihastuti E, Arlinda D, Merati T, Wisaksana R, Lokida D iScience. 2023; 26(10):107986.

PMID: 37854696 PMC: 10579430. DOI: 10.1016/j.isci.2023.107986.


The Update of HIV-1 Prevalence and Incidence and Spatio-Temporal Analyses of HIV Recent Infection Among Four Sub-Groups in Sichuan, China During Surveillance Period Between 2016 and 2022.

Yang H, Li Y, Xu M, Hu Y, Yuan F, Liu L Infect Drug Resist. 2023; 16:6535-6548.

PMID: 37814665 PMC: 10560476. DOI: 10.2147/IDR.S428744.


Monitoring Recently Acquired HIV Infections in Amsterdam, The Netherlands: The Attribution of Test Locations.

Slurink I, van de Baan F, van Sighem A, van Dam A, van de Laar T, de Bree G Front Reprod Health. 2022; 3:568611.

PMID: 36304001 PMC: 9580630. DOI: 10.3389/frph.2021.568611.


Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection.

Mondi A, Pinnetti C, Lorenzini P, Plazzi M, Abbate I, Camici M Pharmaceuticals (Basel). 2022; 15(4).

PMID: 35455400 PMC: 9024471. DOI: 10.3390/ph15040403.